Abstract
We studied the inhibitory effect of human cholangiocarcinoma line (QBC939) treated by selective cyclooxygenase-2 (COX-2) inhibitor NS-398 and provided the theoretical foundation for the clinical practice. Selective COX-2 inhibitor NS-398 on the growth suppression was evaluated by MTT method. The apoptotic rate was quantified and cell cycle by flow cytometry (FCM). Invasive ability was detected by Transwell. The expression of vascular endothelial growth factor (VEGF) and COX-2 in cholangiocarcinoma line was determined by enzyme-linked immunosorbent assay (ELISA). NS-398 could be time-dose dependently inhibited the growth, induced apoptosis, invasived ability, S phase was inhibited, down-regulate the expression of VEGF and COX-2 in cholangiocarcinoma line (QBC939). NS398 can inhibit proliferation of cholangiocarcinoma cell Iine QBC939 and inhibit the invasive ability and induce its apoptosis in vitro, which may contributed to the COX-2 dependent pathway to reduce the release of VEGF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
